Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 May;35(5):461–466. doi: 10.1111/j.1365-2125.1993.tb04170.x

Dose-dependent heart rate reducing effect of nizatidine, a histamine H2-receptor antagonist.

H Hinrichsen 1, A Halabi 1, G Fuhrmann 1, W Kirch 1
PMCID: PMC1381682  PMID: 8099802

Abstract

1. Twelve healthy subjects were treated in a randomised placebo-controlled crossover study with placebo, 150 mg, 300 mg, and 600 mg nizatidine, 100 mg pirenzepine, and 300 mg nizatidine plus 100 mg pirenzepine for 1 week each. 2. On the seventh treatment day, heart rate, blood pressure, systolic time intervals, impedance cardiographic and Doppler ultrasound variables were measured. 3. Stroke volume and blood pressure were not altered by nizatidine and/or pirenzepine. By contrast, heart rate and cardiac output significantly (P < 0.05) decreased in a dose-dependent manner 1.5 and 3 h after administration of 300 and 600 mg nizatidine. Treatment with 150 mg nizatidine led to similar though non-significant trends. 4. While a slightly insignificant rise in heart rate was detected with pirenzepine alone, heart rate and cardiac output remained unchanged upon combined nizatidine and pirenzepine treatment as compared with placebo and baseline values. 5. In conclusion, nizatidine reduced heart rate and cardiac output in a dose-dependent manner, whereas this negative chronotropic effect was counteracted by concurrent administration of the anti-cholinergic drug pirenzepine.

Full text

PDF
461

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aust P. E., Belz G. G., Belz G., Koch W. Comparison of impedance cardiography and echocardiography for measurement of stroke volume. Eur J Clin Pharmacol. 1982;23(6):475–477. doi: 10.1007/BF00637491. [DOI] [PubMed] [Google Scholar]
  2. Baumann G., Felix S. B., Schrader J., Heidecke C. D., Riess G., Erhardt W. D., Ludwig L., Loher U., Sebening F., Blömer H. Cardiac contractile and metabolic effects mediated via the myocardial H2-receptor adenylate cyclase system. Characterization of two new specific H2-receptor agonists, impromidine and dimaprit, in the guinea pig and human myocardium. Res Exp Med (Berl) 1981;179(1):81–98. doi: 10.1007/BF01852128. [DOI] [PubMed] [Google Scholar]
  3. Black J. W., Duncan W. A., Durant C. J., Ganellin C. R., Parsons E. M. Definition and antagonism of histamine H 2 -receptors. Nature. 1972 Apr 21;236(5347):385–390. doi: 10.1038/236385a0. [DOI] [PubMed] [Google Scholar]
  4. Brunner G., Chang J. Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial. Digestion. 1990;45(4):217–225. doi: 10.1159/000200249. [DOI] [PubMed] [Google Scholar]
  5. Callaghan J. T., Bergstrom R. F., Obermeyer B. D., King E. P., Offen W. W. Intravenous nizatidine kinetics and acid suppression. Clin Pharmacol Ther. 1985 Feb;37(2):162–165. doi: 10.1038/clpt.1985.29. [DOI] [PubMed] [Google Scholar]
  6. Callaghan J. T., Bergstrom R. F., Rubin A., Chernish S., Crabtree R., Knadler M. P., Obermeyer B., Offen W. W., Schneck D. W., Aronoff G. A pharmacokinetic profile of nizatidine in man. Scand J Gastroenterol Suppl. 1987;136:9–17. doi: 10.3109/00365528709094480. [DOI] [PubMed] [Google Scholar]
  7. Davis T. G., Pickett D. L., Schlosser J. H. Evaluation of a worldwide spontaneous reporting system with cimetidine. JAMA. 1980 May 16;243(19):1912–1914. [PubMed] [Google Scholar]
  8. Donovan K. D., Dobb G. J., Newman M. A., Hockings B. E., Ireland M. Comparison of pulsed Doppler and thermodilution methods for measuring cardiac output in critically ill patients. Crit Care Med. 1987 Sep;15(9):853–857. doi: 10.1097/00003246-198709000-00011. [DOI] [PubMed] [Google Scholar]
  9. Erbel R., Belz G. G. Untersuchungen zur Messmethode der systolischen Zeitintervalle. Z Kardiol. 1977 Aug;66(8):433–435. [PubMed] [Google Scholar]
  10. Evans J. M., Skidmore R., Luckman N. P., Wells P. N. A new approach to the noninvasive measurement of cardiac output using an annular array Doppler technique--I. Theoretical considerations and ultrasonic fields. Ultrasound Med Biol. 1989;15(3):169–178. doi: 10.1016/0301-5629(89)90061-6. [DOI] [PubMed] [Google Scholar]
  11. Ginsburg R., Bristow M. R., Stinson E. B., Harrison D. C. Histamine receptors in the human heart. Life Sci. 1980 Jun 30;26(26):2245–2249. doi: 10.1016/0024-3205(80)90209-x. [DOI] [PubMed] [Google Scholar]
  12. Halabi A., Kirch W. Cardiovascular effects of omeprazole and famotidine. Scand J Gastroenterol. 1992 Sep;27(9):753–756. doi: 10.3109/00365529209011178. [DOI] [PubMed] [Google Scholar]
  13. Halabi A., Kirch W. Negative chronotropic effects of nizatidine. Gut. 1991 Jun;32(6):630–634. doi: 10.1136/gut.32.6.630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hammer R. Muscarinic receptors in the stomach. Scand J Gastroenterol Suppl. 1980;66:5–11. [PubMed] [Google Scholar]
  15. Hinrichsen H., Halabi A., Kirch W. Haemodynamic effects of H2-receptor antagonists. Eur J Clin Invest. 1992 Jan;22(1):9–18. doi: 10.1111/j.1365-2362.1992.tb01929.x. [DOI] [PubMed] [Google Scholar]
  16. Hinrichsen H., Halabi A., Kirch W. Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther. 1990 Sep;48(3):302–308. doi: 10.1038/clpt.1990.153. [DOI] [PubMed] [Google Scholar]
  17. Hirschowitz B. I., Fong J., Molina E. Effects of pirenzepine and atropine on vagal and cholinergic gastric secretion and gastrin release and on heart rate in the dog. J Pharmacol Exp Ther. 1983 May;225(2):263–268. [PubMed] [Google Scholar]
  18. Humphries T. J., Myerson R. M., Gifford L. M., Aeugle M. E., Josie M. E., Wood S. L., Tannenbaum P. J. A unique postmarket outpatient surveillance program of cimetidine: report on phase II and final summary. Am J Gastroenterol. 1984 Aug;79(8):593–596. [PubMed] [Google Scholar]
  19. Kirch W., Halabi A., Hinrichsen H. Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clin Pharmacol Ther. 1992 Mar;51(3):325–333. doi: 10.1038/clpt.1992.29. [DOI] [PubMed] [Google Scholar]
  20. Kirch W., Halabi A., Linde M., Santos S. R., Ohnhaus E. E. Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology. 1989 Jun;96(6):1388–1392. doi: 10.1016/0016-5085(89)90503-9. [DOI] [PubMed] [Google Scholar]
  21. Kubicek W. G., Karnegis J. N., Patterson R. P., Witsoe D. A., Mattson R. H. Development and evaluation of an impedance cardiac output system. Aerosp Med. 1966 Dec;37(12):1208–1212. [PubMed] [Google Scholar]
  22. MacMahon B., Bakshi M., Walsh M. J. Cardiac arrhythmias after intravenous cimetidine. N Engl J Med. 1981 Oct 1;305(14):832–833. doi: 10.1056/NEJM198110013051414. [DOI] [PubMed] [Google Scholar]
  23. Mayo A., Rawles J. Comparison of four different Doppler instruments used to measure linear and volumetric cardiac output: a study of reproducibility and agreement. Ultrasound Med Biol. 1991;17(4):347–353. doi: 10.1016/0301-5629(91)90134-i. [DOI] [PubMed] [Google Scholar]
  24. Mehta A. B., Goldman J. M. Cimetidine and cardiac dysrhythmias. Ann Intern Med. 1982 Aug;97(2):283–283. doi: 10.7326/0003-4819-97-2-283_1. [DOI] [PubMed] [Google Scholar]
  25. Morton D. M. Pharmacology and toxicology of nizatidine. Scand J Gastroenterol Suppl. 1987;136:1–8. doi: 10.3109/00365528709094479. [DOI] [PubMed] [Google Scholar]
  26. Ng H. W., Walley T., Tsao Y., Breckenridge A. M. Comparison and reproducibility of transthoracic bioimpedance and dual beam Doppler ultrasound measurement of cardiac function in healthy volunteers. Br J Clin Pharmacol. 1991 Sep;32(3):275–282. doi: 10.1111/j.1365-2125.1991.tb03899.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Quail A. W., Traugott F. M. Effects of changing haematocrit, ventricular rate and myocardial inotropy on the accuracy of impedance cardiography. Clin Exp Pharmacol Physiol. 1981 Jul;8(4):335–343. doi: 10.1111/j.1440-1681.1981.tb00737.x. [DOI] [PubMed] [Google Scholar]
  28. Quik R. F., Cooper M. J., Gleeson M., Hentschel E., Schuetze K., Kingston R. D., Mitchell M. A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1990 Apr;4(2):201–211. doi: 10.1111/j.1365-2036.1990.tb00465.x. [DOI] [PubMed] [Google Scholar]
  29. Shah R. R. Symptomatic bradycardia in association with H2-receptor antagonists. Lancet. 1982 Nov 13;2(8307):1108–1108. doi: 10.1016/s0140-6736(82)90038-1. [DOI] [PubMed] [Google Scholar]
  30. Silke B., Verma S. P., Taylor S. H. Pharmacodynamic monitoring during acute intervention in ischaemic heart disease using a new echo-Doppler device. Br J Clin Pharmacol. 1990 Jun;29(6):741–747. doi: 10.1111/j.1365-2125.1990.tb03696.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Watson M., Yamamura H. I., Roeske W. R. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sci. 1983 Jun 27;32(26):3001–3011. doi: 10.1016/0024-3205(83)90652-5. [DOI] [PubMed] [Google Scholar]
  32. Weissler A. M., Harris W. S., Schoenfeld C. D. Systolic time intervals in heart failure in man. Circulation. 1968 Feb;37(2):149–159. doi: 10.1161/01.cir.37.2.149. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES